Drug Trial Radar · NCT05729074
A Study to Evaluate the Safety, Tolerability and Pharmacokinetic Properties of IN-A002 Ointment in Healthy Adult Male Volunteers and Mild to Moderate Atopic Dermatitis Patients
Last checked: Nov 20, 2026Latest source record: Sep 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
81
Actual
Start
Feb 13, 2023
Primary completion
Sep 20, 2024
Study completion Sep 20, 2024
Sponsor
- Lead sponsor
- HK inno.N CorporationIndustry
- Sponsor type
- Industry
- First posted
- Feb 15, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 19 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study aims to evaluate the safety, tolerability and pharmacokinetic properties of IN-A002 Ointment in healthy adult male volunteers and mild to moderate atopic dermatitis patients
Conditions
- Mild to Moderate Atopic Dermatitis
Interventions
IN-A002 Ointment 0.3% or IN-A002 Placebo OintmentDrug
Drug: IN-A002 Ointment 0.3%, 10 g/1000 cm2 Drug: IN-A002 Placebo Ointment, 10 g/1000 cm2
IN-A002 Ointment 0.5% or IN-A002 Placebo OintmentDrug
Drug: IN-A002 Ointment 0.5%, 10 g/1000 cm2, for 1 day Drug: IN-A002 Placebo Ointment, 10 g/1000 cm2, for 1 day
IN-A002 Ointment 1% or IN-A002 Placebo OintmentDrug
Drug: IN-A002 Ointment 1%, 10 g/1000 cm2 Drug: IN-A002 Placebo Ointment, 10 g/1000 cm2
IN-A002 Ointment 3% or IN-A002 Placebo OintmentDrug
Drug: IN-A002 Ointment 3%, 10 g/1000 cm2 Drug: IN-A002 Placebo Ointment, 10 g/1000 cm2
IN-A002 Ointment 5% or IN-A002 Placebo OintmentDrug
Drug: IN-A002 Ointment 5%, 10 g/1000 cm2 Drug: IN-A002 Placebo Ointment, 10 g/1000 cm2
IN-A002 Ointment 1%Drug
Drug: IN-A002 Ointment 1%, 3 g/1000 cm2
IN-A002 Ointment 3%Drug
Drug: IN-A002 Ointment 3%, 3 g/1000 cm2
Elidel Cream 1% (pimecrolimus)Drug
Drug: Elidel Cream 1% (pimecrolimus), 3 g/1000 cm2
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse eventTime frame: Up to post study visit (Day 40)
- Physical examinationTime frame: Up to post study visit (Day 40)
- Clinical Laboratory TestTime frame: Up to post study visit (Day 40)
- Topical Reaction AssessmentTime frame: Predose(0h) at Day 1, Day 8, Day 15, and Day 22, Post-dose(0.5h) at Day 1, Day 8, Day 15, and Day 22, Day 28, Day 29(0h, 0.5h), PSV
- NRS (Numerical Pain Rating Scale)Time frame: Predose(0h) at Day 1, Day 8, Day 15, and Day 22, Post-dose(0.5h) at Day 1, Day 8, Day 15, and Day 22, Day 28, Day 29(0h, 0.5h), PSV
- EASI scoreTime frame: Day 1, Day 8, Day 15, Day 22, Day 29
- IGA scoreTime frame: Day 1, Day 8, Day 15, Day 22, Day 29
- Itch QuestionnaireTime frame: Day 1, Day 8, Day 15, Day 22, Day 29
- Dermatology Life Quality Index (DLQI)Time frame: Day 1, Day 8, Day 15, Day 22, Day 29
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Chungbuk National University Hospital
Cheongju-si, North Chungcheong, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.